Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lycorine hydrochloride thiosulfate is a small molecule antiviral agent being developed by Shandong Dain Marine Biopharmaceutical for the treatment of hand, foot and mouth disease (HFMD). It is a salt form of lycorine, a natural alkaloid extracted from plants in the Amaryllidaceae family. The drug demonstrates potent inhibitory activity against enteroviruses, including Enterovirus 71 (EV71) and Coxsackievirus A16 (CA16), which are the primary causative agents of HFMD. Its mechanism of action involves the inhibition of viral protein synthesis and RNA replication. As of 2024, it is in Phase 1 clinical trials in China to evaluate safety, tolerability, and pharmacokinetics in healthy adults, with the ultimate goal of treating pediatric HFMD.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lycorine hydrochloride thiosulfate.